Apellis Pharmaceuticals Schedules Q3 2025 Earnings Call
LEXINGTON, MA - October 17, 2025 – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today it will release its financial results for the third quarter of 2025 and host a conference call to discuss the results on October 30,2025. The call is scheduled to begin at 8:00 AM Eastern Time.
This earnings call provides a critical update for investors following Apellis’s ongoing commercialization of Syfovre® (pegcetacoplan), its complement inhibitor approved for geographic atrophy secondary to age-related macular degeneration. Analysts and shareholders will be keenly focused on revenue growth, market penetration, and any updates regarding ongoing clinical trials and regulatory submissions. The discussion will offer insights into the company’s financial performance and strategic direction as it navigates the evolving landscape of ophthalmic therapies.
Investors interested in participating in the call can access the live webcast and related materials through the Apellis Pharmaceuticals website.A replay of the call will be available shortly after the conclusion of the live event.
Investor Contact:
Eva Stroynowski
eva.stroynowski@apellis.com
617.938.6229
